ATE509929T1 - Substituierte tricyclische gamma-carbolineals serotonin-rezeptor-agonisten und antagonisten - Google Patents
Substituierte tricyclische gamma-carbolineals serotonin-rezeptor-agonisten und antagonistenInfo
- Publication number
- ATE509929T1 ATE509929T1 AT03808574T AT03808574T ATE509929T1 AT E509929 T1 ATE509929 T1 AT E509929T1 AT 03808574 T AT03808574 T AT 03808574T AT 03808574 T AT03808574 T AT 03808574T AT E509929 T1 ATE509929 T1 AT E509929T1
- Authority
- AT
- Austria
- Prior art keywords
- sup
- antagonists
- receptor agonists
- serotonin receptor
- carbolineals
- Prior art date
Links
- 239000003420 antiserotonin agent Substances 0.000 title 1
- 239000000952 serotonin receptor agonist Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 4
- 208000015114 central nervous system disease Diseases 0.000 abstract 2
- 102000040125 5-hydroxytryptamine receptor family Human genes 0.000 abstract 1
- 108091032151 5-hydroxytryptamine receptor family Proteins 0.000 abstract 1
- 208000019901 Anxiety disease Diseases 0.000 abstract 1
- 208000019695 Migraine disease Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 208000021384 Obsessive-Compulsive disease Diseases 0.000 abstract 1
- 208000028017 Psychotic disease Diseases 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 208000022531 anorexia Diseases 0.000 abstract 1
- 230000036506 anxiety Effects 0.000 abstract 1
- 206010061428 decreased appetite Diseases 0.000 abstract 1
- 238000009472 formulation Methods 0.000 abstract 1
- 206010027599 migraine Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 239000000018 receptor agonist Substances 0.000 abstract 1
- 229940044601 receptor agonist Drugs 0.000 abstract 1
- 239000002464 receptor antagonist Substances 0.000 abstract 1
- 229940044551 receptor antagonist Drugs 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 201000000980 schizophrenia Diseases 0.000 abstract 1
- 208000012201 sexual and gender identity disease Diseases 0.000 abstract 1
- 208000015891 sexual disease Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Engineering & Computer Science (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Heart & Thoracic Surgery (AREA)
- Child & Adolescent Psychology (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Dermatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US43476002P | 2002-12-19 | 2002-12-19 | |
| PCT/US2003/041447 WO2004056324A2 (en) | 2002-12-19 | 2003-12-19 | Substituted tricyclic gamma-carbolines as serotonin receptor agonists and antagonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE509929T1 true ATE509929T1 (de) | 2011-06-15 |
Family
ID=32682101
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT03808574T ATE509929T1 (de) | 2002-12-19 | 2003-12-19 | Substituierte tricyclische gamma-carbolineals serotonin-rezeptor-agonisten und antagonisten |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7109339B2 (de) |
| EP (1) | EP1581221B1 (de) |
| JP (1) | JP4486505B2 (de) |
| AT (1) | ATE509929T1 (de) |
| AU (1) | AU2003303210A1 (de) |
| ES (1) | ES2364046T3 (de) |
| IS (1) | IS7891A (de) |
| NO (1) | NO20052728L (de) |
| PL (1) | PL377426A1 (de) |
| WO (1) | WO2004056324A2 (de) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2002066494A2 (en) * | 2001-02-16 | 2002-08-29 | Bristol-Myers Squibb Company | Identification and cloning of a novel human gene, ret16, involved in the intracellular signaling cascade |
| SE0203712D0 (sv) | 2002-12-13 | 2002-12-13 | Astrazeneca Ab | Novel compounds |
| US8598219B2 (en) | 2003-01-30 | 2013-12-03 | Helsinn Healthcare Sa | Liquid pharmaceutical formulations of palonosetron |
| JO2735B1 (en) * | 2003-01-30 | 2013-09-15 | هيلسين هيلث كير أس ايه. | Liquid pharmaceutical formulations of palonosetron |
| WO2005095396A1 (en) * | 2004-03-05 | 2005-10-13 | Pharma C S.A. | 8-phenoxy-ϝ carboline derivatives |
| US7592454B2 (en) | 2004-04-14 | 2009-09-22 | Bristol-Myers Squibb Company | Substituted hexahydro-pyridoindole derivatives as serotonin receptor agonists and antagonists |
| US7572805B2 (en) * | 2004-07-14 | 2009-08-11 | Bristol-Myers Squibb Company | Pyrrolo(oxo)isoquinolines as 5HT ligands |
| JP5173190B2 (ja) | 2004-08-25 | 2013-03-27 | 武田薬品工業株式会社 | 腹圧性尿失禁の予防・治療剤及びそのスクリーニング方法 |
| CN101094689B (zh) * | 2004-11-01 | 2013-06-12 | 安米林药品有限责任公司 | 治疗肥胖以及肥胖相关疾病和病症的方法 |
| US8394765B2 (en) | 2004-11-01 | 2013-03-12 | Amylin Pharmaceuticals Llc | Methods of treating obesity with two different anti-obesity agents |
| AU2005305036B2 (en) * | 2004-11-01 | 2011-03-10 | Amylin Pharmaceuticals, Llc | Treatment of obesity and related disorders |
| AR051946A1 (es) * | 2004-11-05 | 2007-02-21 | Wyeth Corp | Formulaciones de derivados de [1,4] diazepina [6,7,1-ij] quinolina |
| TW200635926A (en) * | 2004-11-05 | 2006-10-16 | Wyeth Corp | Metabolites of ceratin [1,4]diazepino[6,7,1-ij]quinoline derivatives and methods of preparation and use thereof |
| KR20080034171A (ko) * | 2005-07-28 | 2008-04-18 | 브리스톨-마이어스 스큅 컴퍼니 | 세로토닌 수용체 효능제 및 길항제로서의 치환된테트라히드로-1ｈ-피리도[4,3,ｂ]인돌 |
| MY145464A (en) | 2005-08-31 | 2012-02-15 | Hoffmann La Roche | Pyrazolone derivatives as 11-beta hsd1 inhibitors |
| RU2338537C2 (ru) * | 2006-01-25 | 2008-11-20 | Сергей Олегович Бачурин | СРЕДСТВО ДЛЯ ЛЕЧЕНИЯ ШИЗОФРЕНИИ НА ОСНОВЕ ГИДРИРОВАННЫХ ПИРИДО(4,3-b)ИНДОЛОВ (ВАРИАНТЫ), ФАРМАКОЛОГИЧЕСКОЕ СРЕДСТВО НА ЕГО ОСНОВЕ И СПОСОБ ЕГО ПРИМЕНЕНИЯ |
| EP2727585A1 (de) | 2006-05-16 | 2014-05-07 | Takeda Pharmaceutical Company Limited | In-vivo Screening-Methode |
| RU2329044C1 (ru) * | 2006-11-16 | 2008-07-20 | Андрей Александрович Иващенко | Лиганды 5-ht6 рецепторов, фармацевтическая композиция, способ ее получения и лекарственное средство |
| KR102107954B1 (ko) * | 2007-03-12 | 2020-05-07 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 치환된 헤테로환 융합 감마-카르볼린 합성 |
| RU2338745C1 (ru) * | 2007-03-21 | 2008-11-20 | Андрей Александрович Иващенко | ЗАМЕЩЕННЫЕ 2,3,4,5-ТЕТРАГИДРО-1Н-ПИРИДО[4,3-b]ИНДОЛЫ, СПОСОБЫ ИХ ПОЛУЧЕНИЯ И ПРИМЕНЕНИЯ |
| MX2009012788A (es) * | 2007-05-25 | 2010-01-14 | Medivation Neurology Inc | Metodos y composiciones para estimular celulas. |
| WO2009001129A1 (en) | 2007-06-26 | 2008-12-31 | Astrazeneca Ab | 1-cyanocyclopropyl-derivatives as cathepsin k inhibitors |
| AU2008302751A1 (en) * | 2007-09-20 | 2009-03-26 | D2E, Llc | Fluoro-containing derivatives of hydrogenated pyrido[4,3-b]indoles with neuroprotective and cognition enhancing properties, process for preparing, and use |
| EP2789338A3 (de) | 2007-11-15 | 2015-01-14 | Takeda Pharmaceutical Company Limited | Kondensiertes Pyridinderivat und seine Verwendung |
| US8575186B2 (en) | 2009-10-05 | 2013-11-05 | Albany Molecular Research, Inc. | Epiminocycloalkyl[b] indole derivatives as serotonin sub-type 6 (5-HT6) modulators and uses thereof |
| EP2510949A4 (de) | 2009-12-11 | 2013-11-13 | Astellas Pharma Inc | Therapeutikum für fibromyalgie |
| WO2011103433A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Pyrido[4,3-b]indole and pyrido[3,4-b]indole derivatives and methods of use |
| US9040519B2 (en) | 2010-02-18 | 2015-05-26 | Medivation Technologies, Inc. | Fused tetracyclic pyrido [4,3-B] indole and pyrido [3,4-B] indole derivatives and methods of use |
| WO2011103460A1 (en) | 2010-02-18 | 2011-08-25 | Medivation Technologies, Inc. | Fused tetracyclic pyrido[4,3-b]indole and pyrido[3,4-b]ondole derivatives and methods of use |
| CA2796756A1 (en) * | 2010-04-22 | 2011-10-27 | Intra-Cellular Therapies, Inc. | Substituted pyrido(3',4':4,5)pyrrolo(1,2,3-de)quinoxalines for the treatment of central nervous system disorders |
| US20130267500A1 (en) | 2010-09-01 | 2013-10-10 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists in the treatment of disorders ameliorated by reduction of norepinephrine level |
| EP2668191A4 (de) | 2011-01-19 | 2014-08-20 | Albany Molecular Res Inc | Benzofuro-[3,2-c-]pyridine und verwandte analoga als serotonin-untertyp-6 (5-ht6)-modulatoren zur behandlung von adipositas, stoffwechselsyndrom, kognition und schizophrenie |
| US9434747B2 (en) | 2011-02-18 | 2016-09-06 | Medivation Technologies, Inc. | Methods of treating diabetes |
| KR20140146192A (ko) | 2012-04-14 | 2014-12-24 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 유기 화합물 |
| US9708322B2 (en) | 2013-03-15 | 2017-07-18 | Intra-Cellular Therapies, Inc. | Substituted pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalines for inhibiting serotonin reuptake transporter activity |
| WO2015066344A1 (en) | 2013-11-01 | 2015-05-07 | Arena Pharmaceuticals, Inc. | 5-ht2c receptor agonists and compositions and methods of use |
| KR102373288B1 (ko) | 2013-12-03 | 2022-03-10 | 인트라-셀룰라 써래피스, 인코퍼레이티드. | 신규한 방법 |
| US10077267B2 (en) | 2014-04-04 | 2018-09-18 | Intra-Cellular Therapies, Inc. | Organic compounds |
| CA2944755A1 (en) | 2014-04-04 | 2015-10-08 | Intra-Cellular Therapies, Inc. | Organic compounds |
| PL3838274T3 (pl) | 2016-01-26 | 2024-04-02 | Intra-Cellular Therapies, Inc. | Pochodna pirydo[3',4':4,5]pirolo[1,2,3-DE]chinoksaliny do zastosowania w leczeniu zaburzeń OUN |
| DK3407889T3 (da) | 2016-03-25 | 2021-08-09 | Intra Cellular Therapies Inc | Organiske forbindelser og deres anvendelse til behandling og forebyggelse af lidelser i centralnervesystemet |
| US10682354B2 (en) | 2016-03-28 | 2020-06-16 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| US11014925B2 (en) | 2016-03-28 | 2021-05-25 | Intra-Cellular Therapies, Inc. | Co-crystals of 1-(4-fluoro-phenyl)-4-((6bR,1OaS)-3-methyl-2,3,6b,9,10,10a-hexahydro-1H,7H- pyrido[3′,4′:4,51_pyrrolo [1,2,3-delqcuinoxalin-8-yl)-butan-1-one with nicotinamide or isonicotinamide |
| EP3436455A4 (de) | 2016-03-28 | 2019-09-04 | Intra-Cellular Therapies, Inc. | Neuartige salze und kristalle |
| EP3525763B1 (de) | 2016-10-12 | 2025-03-05 | Intra-Cellular Therapies, Inc. | Amorphe feste dispersionen |
| WO2018111805A1 (en) | 2016-12-13 | 2018-06-21 | St. Jude Children's Research Hospital | Tetrahydroquinoline-based bromodomain inhibitors |
| EP3562484B1 (de) | 2016-12-29 | 2021-08-25 | Intra-Cellular Therapies, Inc. | Pyrido[3',4':4,5]pyrrolo[1,2,3-de]quinoxalinderivate zur behandlung von erkrankungen des zns |
| WO2018126140A1 (en) | 2016-12-29 | 2018-07-05 | Intra-Cellular Therapies, Inc. | Organic compounds |
| RU2767410C2 (ru) | 2017-03-24 | 2022-03-17 | Интра-Селлулар Терапиз, Инк. | Новые композиции и способы |
| US11207322B2 (en) | 2017-04-28 | 2021-12-28 | Board Of Regents, The University Of Texas System | Method and composition related to combination therapy for addiction |
| EP3658144B1 (de) | 2017-07-26 | 2022-01-26 | Intra-Cellular Therapies, Inc. | Pyridopyrroloquinoxalinverbindungen, deren zusammensetzungen und verwendungen in therapie |
| WO2019023062A1 (en) | 2017-07-26 | 2019-01-31 | Intra-Cellular Therapies, Inc. | ORGANIC COMPOUNDS |
| US11440911B2 (en) | 2017-09-26 | 2022-09-13 | Intra-Cellular Therapies, Inc. | Salts and crystals |
| US20210052600A1 (en) | 2017-12-27 | 2021-02-25 | Takeda Pharmaceutical Company Limited | Therapeutic agents for stress urinary incontinence and incotinence of feces |
| CN112040940A (zh) | 2018-03-23 | 2020-12-04 | 细胞内治疗公司 | 有机化合物 |
| AU2019280850C1 (en) | 2018-06-06 | 2025-02-13 | Intra-Cellular Therapies, Inc. | Novel salts and crystals |
| EP3801527B1 (de) | 2018-06-08 | 2025-02-19 | Intra-Cellular Therapies, Inc. | Anellierte gamma-carboline zur akutbehandlung von angst oder depression |
| CA3240552A1 (en) | 2018-06-11 | 2019-12-19 | Intra-Cellular Therapies, Inc. | Substituted heterocycle fused gamma-carbolines synthesis |
| US12144808B2 (en) | 2018-08-29 | 2024-11-19 | Intra-Cellular Therapies, Inc. | Compositions and methods |
| BR112021003655A2 (pt) | 2018-08-31 | 2021-05-18 | Intra-Cellular Therapies, Inc. | métodos novos |
| WO2020047408A1 (en) | 2018-08-31 | 2020-03-05 | Intra-Cellular Therapies, Inc. | Novel methods |
| WO2020185581A2 (en) * | 2019-03-08 | 2020-09-17 | The Regents Of The University Of California | Compositions and methods for modulating lipid and steroid metabolism |
| WO2021007245A1 (en) | 2019-07-07 | 2021-01-14 | Intra-Cellular Therapies, Inc. | Novel methods |
| EP4072554A4 (de) | 2019-12-11 | 2023-12-20 | Intra-Cellular Therapies, Inc. | Organische verbindung |
| AU2022310353A1 (en) * | 2021-07-14 | 2024-02-01 | Northeastern University | Serotonin 5-ht2a, 5-ht2b, and 5-ht2c receptor inverse agonists |
| CN114105985B (zh) * | 2021-12-13 | 2024-04-16 | 南方科技大学坪山生物医药研究院 | 不对称氢化构建卢美哌隆中间体的方法及卢美哌隆中间体 |
| US12414948B2 (en) | 2022-05-18 | 2025-09-16 | Intra-Cellular Therapies, Inc. | Methods |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4238607A (en) * | 1972-06-19 | 1980-12-09 | Endo Laboratories Inc. | Pyridopyrrolo benzheterocycles |
| US4183936A (en) * | 1972-06-19 | 1980-01-15 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US3914421A (en) * | 1972-06-19 | 1975-10-21 | Endo Lab | Pyridopyrrolobenzheterocycles for combatting depression |
| US4013652A (en) * | 1972-06-19 | 1977-03-22 | Endo Laboratories, Inc. | Pyridopyrrolobenzoxazine |
| US4115577A (en) * | 1972-06-19 | 1978-09-19 | Endo Laboratories, Inc. | Pyridopyrrolobenzheterocycles |
| US4219550A (en) * | 1978-11-09 | 1980-08-26 | E. I. Du Pont De Nemours And Company | Cis- and trans- octahydropyridopyrrolobenzheterocycles |
| HUT61548A (en) | 1990-08-27 | 1993-01-28 | Sandoz Ag | Process for producing indolonaphthyridine derivatives and pharmaceutical compositions comprising such compounds |
| JP3108483B2 (ja) * | 1991-09-30 | 2000-11-13 | 日清製粉株式会社 | インドール誘導体およびこれを有効成分とする抗潰瘍薬 |
| TW470745B (en) * | 1996-05-23 | 2002-01-01 | Janssen Pharmaceutica Nv | Hexahydro-pyrido[4,3-b]indole derivatives |
| NZ512765A (en) | 1998-12-17 | 2003-10-31 | Wyeth Corp | 2,3,4,4A-tetrahydro-1H-pyrazino(1,2-A)quinoxalin- 5(6H)one derivatives being 5HT2C agonists |
| ATE277048T1 (de) | 1999-06-15 | 2004-10-15 | Bristol Myers Squibb Pharma Co | Substituierte hetercyclisch kondensierte gamma carboline |
| SK7042003A3 (en) | 2000-12-20 | 2004-07-07 | Bristol Myers Squibb Co | Substituted pyridoindoles as serotonin agonists and antagonists |
| CA2453537A1 (en) * | 2001-08-08 | 2003-02-20 | Pharmacia & Upjohn Company | Therapeutic 1h-pyrido¬4,3-b|indoles |
-
2003
- 2003-12-19 WO PCT/US2003/041447 patent/WO2004056324A2/en not_active Ceased
- 2003-12-19 ES ES03808574T patent/ES2364046T3/es not_active Expired - Lifetime
- 2003-12-19 AU AU2003303210A patent/AU2003303210A1/en not_active Abandoned
- 2003-12-19 AT AT03808574T patent/ATE509929T1/de not_active IP Right Cessation
- 2003-12-19 PL PL377426A patent/PL377426A1/pl not_active Application Discontinuation
- 2003-12-19 EP EP03808574A patent/EP1581221B1/de not_active Expired - Lifetime
- 2003-12-19 JP JP2004561460A patent/JP4486505B2/ja not_active Expired - Fee Related
- 2003-12-19 US US10/743,449 patent/US7109339B2/en not_active Expired - Lifetime
-
2005
- 2005-06-07 NO NO20052728A patent/NO20052728L/no not_active Application Discontinuation
- 2005-06-10 IS IS7891A patent/IS7891A/is unknown
Also Published As
| Publication number | Publication date |
|---|---|
| AU2003303210A1 (en) | 2004-07-14 |
| WO2004056324A2 (en) | 2004-07-08 |
| US7109339B2 (en) | 2006-09-19 |
| EP1581221B1 (de) | 2011-05-18 |
| AU2003303210A8 (en) | 2004-07-14 |
| PL377426A1 (pl) | 2006-02-06 |
| ES2364046T3 (es) | 2011-08-23 |
| JP2006511568A (ja) | 2006-04-06 |
| JP4486505B2 (ja) | 2010-06-23 |
| WO2004056324A3 (en) | 2004-09-02 |
| US20040180875A1 (en) | 2004-09-16 |
| NO20052728D0 (no) | 2005-06-07 |
| EP1581221A4 (de) | 2008-11-26 |
| IS7891A (is) | 2005-06-10 |
| EP1581221A2 (de) | 2005-10-05 |
| NO20052728L (no) | 2005-08-23 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE509929T1 (de) | Substituierte tricyclische gamma-carbolineals serotonin-rezeptor-agonisten und antagonisten | |
| DE60139511D1 (de) | Substituierte pyrrolochinoline und pyridochinoline als serotonin- agonisten und- antagonisten | |
| WO2002059129A3 (en) | Substituted tetracyclic pyridoindoles as serotonin agonists and antagonists | |
| HK1043112A1 (zh) | 取代的稠杂环γ-咔啉 | |
| NO20071660L (no) | Nye pyridinonderivater og deres anvendelse som positive allosteriske modulatorer av MGLUR2-reseptorer | |
| EP1392298A4 (de) | Kondensierte heterozyklische verbindungen | |
| NO20055029L (no) | Nye piperidinylamino-tieno[2,3-di]pyrimidinforbindelser | |
| NO20032795D0 (no) | Substituerte pyrazinokinoksalinderivater som serotonin reseptor agonister og antagonister | |
| GB0311349D0 (en) | Therapeutic agents, compositions, preparations and uses | |
| WO2004018482A3 (en) | C6- and c9-substituted chromeno[4, 3-c]isoxazoline derivatives and their use as anti-depressants |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |